HOW WE HELP

0
FUNDING TO NET CANCER RESEARCH PROJECTS
0
ANNUAL VISITORS TO WEBSITE & RESOURCES
0
ANNUAL EMAIL, PHONE & ONLINE INQUIRIES
0
NET PATIENT EDUCATIONAL SESSIONS
0
NET GUIDES DISTRIBUTED ACROSS CANADA
0
COMBINED SOCIAL MEDIA MEMBERS/FOLLOWERS
0
PATIENT & CAREGIVER SUPPORT GROUP MEMBERS
0
PATIENT ADVOCACY FOR ACCESS TO TREATMENTS

NET Cancer is the FASTEST growing class of CANCER worldwide

HELP US HELP OTHERS
HELP US HELP OTHERS

NET CANCER AWARENESS

Easily missed.

Take a closer look at neuroendocrine cancer.

Understanding RLT in NETs

ENGLISH

FRENCH

NEUROENDOCRINE TUMOURS (NETs) OVERVIEW

  • Neuroendocrine tumours (NETs) are abnormal growth of cells (neoplasms) that arise from cells of the diffuse neuroendocrine system.

  • NETs are considered complex tumours because both tumor growth and hormonal function must be addressed.

  • NETs are most common in the lung or gastrointestinal system, but they can also originate in other parts of the body such as the thyroid, thymus, pancreas, adrenals, paraganglia, ovaries and testes.

  • NETs are classified as functional (produce hormones that cause symptoms), or non-functional (may or may not produce hormones and do not cause hormonal symptoms).

  • The cause of NETs is currently unknown.

NET ONE PAGE FACTS

CNETS NEWS

NET Biomarkers Guideline Published in JAMA Oncology

CNETS is thrilled to announce the publication of a biomarker guideline and patient supplements in JAMA Oncology. Citation: Loree JM, Chan D, Lim J, et al. Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic [...]

Welireg (belzutifan): pCPA Negotiations

The pan-Canadian Pharmaceutical Alliance (pCPA) negotiation process for Welireg (belzutifan) concluded on 2024-08-30. Indication(s): Von Hippel-Lindau (VHL) disease in adult patients who require therapy for associated non-metastatic renal cell carcinoma (RCC), central nervous system (CNS) [...]

Update on Lutathera pCPA Negotiations for pNETs

One step closer to access to Lutathera for pNETs patients! The pan-Canadian Pharmaceutical Alliance (pCPA) negotiations with Advanced Accelerator Applications for Lutathera (lutetium 177 dotatate) in pNETs  concluded on 2023-10-17. Negotiation Status: Concluded with [...]

Board Recruitment Announcement

Are you looking for a unique leadership opportunity? Have you been yearning to put your talent in strategic thinking, financial analysis, project management, communications or policy advocacy in the service of a great cause?  Well, [...]

Somatuline Motorized Delivery Device – Press Release

Ipsen announces investment in new state-of-the-art electronic autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) designed to improve patient experience. New electronic autoinjector is designed to improve patient experience for people living with gastroenteropancreatic neuroendocrine [...]

CNETS PRIORITIES

AWARENESS

– Raise awareness of NET cancer to the general public & the medical community

– Participate in World NET Cancer Day Activities

SUPPORT

– In-person peer-led support groups meetings

– Dedicated patient email and phone support

– Online private support groups for patients & caregivers

EDUCATION

– Patient and caregiver education sessions across Canada

– Robust online patient educational resources

– Printed educational resources including the NET Reference Guide

– Annual NET Medical and Scientific Meeting

ADVOCACY

– Assist patients in advocating for access to treatments and diagnostics

RESEARCH

– Fund Canadian NET cancer research projects

Share This Page, Choose Your Platform!